Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry

scientific article

Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/BMC.44
P698PubMed publication ID11268051

P2093author name stringOguma T
Konno T
Inaba A
Nakaoka M
P2860cites workDX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variantQ41094672
A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.Q54167076
Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detectionQ73814722
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude miceQ74824090
P4510describes a project that useshigh-performance liquid chromatographyQ381233
P433issue2
P921main subjectatmospheric pressureQ81809
high-performance liquid chromatographyQ381233
P304page(s)108-115
P577publication date2001-04-01
P1433published inBiomedical ChromatographyQ4915104
P1476titleValidation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry
P478volume15

Reverse relations

cites work (P2860)
Q46679640A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
Q44715299A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum
Q34510279Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods.
Q33194418Clinical studies of camptothecin and derivatives
Q74266892Current literature in mass spectrometry